Cooperative group research efforts in thoracic malignancies 2009: A review from the 10th annual international lung cancer congress

Heather Wakelee, Bill W. Loo, Kemp H. Kernstine, Joe Bill Putnam, Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Critical advances in the treatment of patients with lung cancer have occurred in the past few years. The cooperative groups in North America and internationally have played crucial roles in these advances. The leaders of the groups meet on a regular basis to review the progress of their trials. However, they rarely have a chance to discuss all ongoing and planned trials, except at the annual Lung Cancer Congress held each June. This article captures this exchange from the 10th Annual Lung Cancer Congress held in June 2009. Exciting efforts are ongoing for all stages of non-small-cell lung cancer, small-cell lung cancer, and mesothelioma. A major focus of the groups at this time is a push toward more personalized medicine, as reflected in the selection criteria for many of the trials, along with planned correlates to better define populations most likely to benefit. Agents targeting the vascular endothelial growth factor (VEGF) pathway, including many tyrosine kinase inhibitors against the VEGF receptor, and those targeting the epidermal growth factor receptor pathway, are under extensive development with many combination trials ongoing.

Original languageEnglish (US)
Pages (from-to)395-404
Number of pages10
JournalClinical Lung Cancer
Volume10
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Lung Neoplasms
Thorax
Research
Neoplasms
Precision Medicine
Vascular Endothelial Growth Factor Receptor
Mesothelioma
Small Cell Lung Carcinoma
North America
Focus Groups
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Patient Selection
Vascular Endothelial Growth Factor A
Population
Therapeutics

Keywords

  • Bevacizumab
  • Cediranib
  • Cetuximab
  • EGFR mutational status
  • Mesothelioma
  • Sunitinib
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Cooperative group research efforts in thoracic malignancies 2009 : A review from the 10th annual international lung cancer congress. / Wakelee, Heather; Loo, Bill W.; Kernstine, Kemp H.; Putnam, Joe Bill; Edelman, Martin J.; Vokes, Everett E.; Schiller, Joan H.; Baas, Paul; Saijo, Nagahiro; Adjei, Alex; Goss, Glenwood; Choy, Hak; Gandara, David R.

In: Clinical Lung Cancer, Vol. 10, No. 6, 2009, p. 395-404.

Research output: Contribution to journalArticle

Wakelee, H, Loo, BW, Kernstine, KH, Putnam, JB, Edelman, MJ, Vokes, EE, Schiller, JH, Baas, P, Saijo, N, Adjei, A, Goss, G, Choy, H & Gandara, DR 2009, 'Cooperative group research efforts in thoracic malignancies 2009: A review from the 10th annual international lung cancer congress', Clinical Lung Cancer, vol. 10, no. 6, pp. 395-404. https://doi.org/10.3816/CLC.2009.n.075
Wakelee, Heather ; Loo, Bill W. ; Kernstine, Kemp H. ; Putnam, Joe Bill ; Edelman, Martin J. ; Vokes, Everett E. ; Schiller, Joan H. ; Baas, Paul ; Saijo, Nagahiro ; Adjei, Alex ; Goss, Glenwood ; Choy, Hak ; Gandara, David R. / Cooperative group research efforts in thoracic malignancies 2009 : A review from the 10th annual international lung cancer congress. In: Clinical Lung Cancer. 2009 ; Vol. 10, No. 6. pp. 395-404.
@article{b89474bc671142028e19978f9d65ca29,
title = "Cooperative group research efforts in thoracic malignancies 2009: A review from the 10th annual international lung cancer congress",
abstract = "Critical advances in the treatment of patients with lung cancer have occurred in the past few years. The cooperative groups in North America and internationally have played crucial roles in these advances. The leaders of the groups meet on a regular basis to review the progress of their trials. However, they rarely have a chance to discuss all ongoing and planned trials, except at the annual Lung Cancer Congress held each June. This article captures this exchange from the 10th Annual Lung Cancer Congress held in June 2009. Exciting efforts are ongoing for all stages of non-small-cell lung cancer, small-cell lung cancer, and mesothelioma. A major focus of the groups at this time is a push toward more personalized medicine, as reflected in the selection criteria for many of the trials, along with planned correlates to better define populations most likely to benefit. Agents targeting the vascular endothelial growth factor (VEGF) pathway, including many tyrosine kinase inhibitors against the VEGF receptor, and those targeting the epidermal growth factor receptor pathway, are under extensive development with many combination trials ongoing.",
keywords = "Bevacizumab, Cediranib, Cetuximab, EGFR mutational status, Mesothelioma, Sunitinib, Vinorelbine",
author = "Heather Wakelee and Loo, {Bill W.} and Kernstine, {Kemp H.} and Putnam, {Joe Bill} and Edelman, {Martin J.} and Vokes, {Everett E.} and Schiller, {Joan H.} and Paul Baas and Nagahiro Saijo and Alex Adjei and Glenwood Goss and Hak Choy and Gandara, {David R.}",
year = "2009",
doi = "10.3816/CLC.2009.n.075",
language = "English (US)",
volume = "10",
pages = "395--404",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Cooperative group research efforts in thoracic malignancies 2009

T2 - A review from the 10th annual international lung cancer congress

AU - Wakelee, Heather

AU - Loo, Bill W.

AU - Kernstine, Kemp H.

AU - Putnam, Joe Bill

AU - Edelman, Martin J.

AU - Vokes, Everett E.

AU - Schiller, Joan H.

AU - Baas, Paul

AU - Saijo, Nagahiro

AU - Adjei, Alex

AU - Goss, Glenwood

AU - Choy, Hak

AU - Gandara, David R.

PY - 2009

Y1 - 2009

N2 - Critical advances in the treatment of patients with lung cancer have occurred in the past few years. The cooperative groups in North America and internationally have played crucial roles in these advances. The leaders of the groups meet on a regular basis to review the progress of their trials. However, they rarely have a chance to discuss all ongoing and planned trials, except at the annual Lung Cancer Congress held each June. This article captures this exchange from the 10th Annual Lung Cancer Congress held in June 2009. Exciting efforts are ongoing for all stages of non-small-cell lung cancer, small-cell lung cancer, and mesothelioma. A major focus of the groups at this time is a push toward more personalized medicine, as reflected in the selection criteria for many of the trials, along with planned correlates to better define populations most likely to benefit. Agents targeting the vascular endothelial growth factor (VEGF) pathway, including many tyrosine kinase inhibitors against the VEGF receptor, and those targeting the epidermal growth factor receptor pathway, are under extensive development with many combination trials ongoing.

AB - Critical advances in the treatment of patients with lung cancer have occurred in the past few years. The cooperative groups in North America and internationally have played crucial roles in these advances. The leaders of the groups meet on a regular basis to review the progress of their trials. However, they rarely have a chance to discuss all ongoing and planned trials, except at the annual Lung Cancer Congress held each June. This article captures this exchange from the 10th Annual Lung Cancer Congress held in June 2009. Exciting efforts are ongoing for all stages of non-small-cell lung cancer, small-cell lung cancer, and mesothelioma. A major focus of the groups at this time is a push toward more personalized medicine, as reflected in the selection criteria for many of the trials, along with planned correlates to better define populations most likely to benefit. Agents targeting the vascular endothelial growth factor (VEGF) pathway, including many tyrosine kinase inhibitors against the VEGF receptor, and those targeting the epidermal growth factor receptor pathway, are under extensive development with many combination trials ongoing.

KW - Bevacizumab

KW - Cediranib

KW - Cetuximab

KW - EGFR mutational status

KW - Mesothelioma

KW - Sunitinib

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=74949117651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949117651&partnerID=8YFLogxK

U2 - 10.3816/CLC.2009.n.075

DO - 10.3816/CLC.2009.n.075

M3 - Article

C2 - 19900856

AN - SCOPUS:74949117651

VL - 10

SP - 395

EP - 404

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -